Skip to main content
. 2008 Sep 5;112(12):4425–4431. doi: 10.1182/blood-2008-07-169342

Figure 1.

Figure 1

Treatment-related mortality. Treatment-related mortality was examined in a competing risk fashion, with relapse as the competing risk. The 1-year cumulative incidence of TRM in the Tac/Sir group was 13% compared with 30% in the Tac/Sir/Mtx group and 26% in the Tac/Mtx group (P < .001).